Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Organic Chemicals
Organophosphorus Compounds
Clear Filters

Search Clinical Trials

50 Results
Terminated
T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
To participate in this transplant, the patient will need to have a central line. Before the transplant we will test the blood for viruses which can cause problems after the …
Baylor Role: Lead Sponsor
Terminated
T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
Before the transplant we will test the patients blood for viruses which can cause problems after the transplant. These viruses include Hepatitis B, (which causes liver damage), cytomegalovirus, (which causes …
Baylor Role: Lead Sponsor
Completed
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
Induction Phase Overview The induction phase is approximately 15 weeks long. Chemotherapy is generally given every 3 weeks, each 3 week block is called a "cycle". During these 15 weeks …
Baylor Role: Lead Sponsor
Completed
Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)
This is a Phase 1, open-label, dose-escalating study of karenitecin plus cyclophosphamide in the treatment of pediatric patients with refractory or recurrent solid tumors. All patients must have histologically documented …
Baylor Role: Lead Sponsor
Terminated
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
Prior to any bone marrow transplant, we will need patients to: - Answer questions about their medical history; - Undergo a physical examination; - Have tests done to see how …
Baylor Role: Collaborator
Completed
Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
Zoledronic Acid (Zometa), a new generation, highly potent bisphosphonate used to treat osteoporosis and hypercalcemia of malignancy, is widely used in adult malignancies with potential for bone metastasis such as …
Baylor Role: Lead Sponsor
Completed
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Large clinical trials have confirmed the value of systemic adjuvant therapy in decreasing the risk of recurrence and death in patients with early breast cancer. However, the need to identify …
Baylor Role: Collaborator
Active, Not Recruiting
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
In order to transplant stem cells we will need to give the patient drugs or high-dose chemotherapy to kill or destroy most of the blood forming and immune cells in …
Baylor Role: Lead Sponsor
Terminated
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
To be treated on this study, we will test the blood to check for viruses, including HIV (the virus that causes AIDS). If the HIV test is positive, a transplant …
Baylor Role: Lead Sponsor
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role: Lead Sponsor